Adverum Biotechnologies Inc (ADVM)
5.85
+0.10
(+1.74%)
USD |
NASDAQ |
Nov 22, 09:52
Adverum Biotechnologies Revenue (Quarterly): 1.00M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.00M |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | 3.60M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 7.50M |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | 0.25M |
| June 30, 2019 |
| Date | Value |
|---|---|
| March 31, 2019 | |
| December 31, 2018 | 0.07M |
| September 30, 2018 | 0.833M |
| June 30, 2018 | 0.493M |
| March 31, 2018 | 0.216M |
| December 31, 2017 | 0.461M |
| September 30, 2017 | 0.463M |
| June 30, 2017 | 0.463M |
| March 31, 2017 | 0.462M |
| December 31, 2016 | 0.488M |
| September 30, 2016 | 0.395M |
| June 30, 2016 | 0.307M |
| March 31, 2016 | 0.265M |
| December 31, 2015 | 0.96M |
| September 30, 2015 | 0.953M |
| June 30, 2015 | 0.203M |
| March 31, 2015 | 0.203M |
| December 31, 2014 | 0.203M |
| September 30, 2014 | 0.204M |
| June 30, 2014 | 0.135M |
| March 31, 2014 | 0.03M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.00M
Minimum
Sep 2024
7.50M
Maximum
Mar 2021
4.033M
Average
3.60M
Median
Mar 2023
Revenue (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | 10.52M |
| Cassava Sciences Inc | -- |
| Regenxbio Inc | 24.20M |
| Editas Medicine Inc | 0.061M |
| Apellis Pharmaceuticals Inc | 196.83M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -27.13M |
| Total Expenses (Quarterly) | 30.22M |
| EPS Diluted (Quarterly) | -1.30 |
| Enterprise Value | -33.63M |
| Profit Margin (Quarterly) | -2.71K% |
| Earnings Yield | -102.7% |
| Normalized Earnings Yield | -102.74 |